Epoch Investment Partners Inc. Buys 39,526 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Epoch Investment Partners Inc. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,266 shares of the biopharmaceutical company's stock after acquiring an additional 39,526 shares during the quarter. Epoch Investment Partners Inc. owned approximately 0.18% of Regeneron Pharmaceuticals worth $140,518,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in REGN. Forum Financial Management LP lifted its holdings in Regeneron Pharmaceuticals by 13.6% in the 4th quarter. Forum Financial Management LP now owns 916 shares of the biopharmaceutical company's stock worth $652,000 after purchasing an additional 110 shares in the last quarter. Freedom Investment Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 6.5% in the fourth quarter. Freedom Investment Management Inc. now owns 805 shares of the biopharmaceutical company's stock worth $574,000 after buying an additional 49 shares in the last quarter. Capital International Ltd. CA lifted its holdings in shares of Regeneron Pharmaceuticals by 14.5% in the fourth quarter. Capital International Ltd. CA now owns 40,968 shares of the biopharmaceutical company's stock worth $29,183,000 after buying an additional 5,197 shares in the last quarter. Commerce Bank boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the fourth quarter. Commerce Bank now owns 6,804 shares of the biopharmaceutical company's stock worth $4,847,000 after acquiring an additional 89 shares during the last quarter. Finally, Capital Group Investment Management PTE. LTD. grew its stake in Regeneron Pharmaceuticals by 17.1% during the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 8,743 shares of the biopharmaceutical company's stock valued at $6,228,000 after acquiring an additional 1,275 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on REGN shares. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a report on Friday, January 10th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday. They set an "overweight" rating and a $695.00 price target for the company. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. Finally, Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $949.60.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ REGN traded up $4.05 during trading hours on Thursday, reaching $591.90. The stock had a trading volume of 484,154 shares, compared to its average volume of 717,526. The business's fifty day moving average price is $640.41 and its two-hundred day moving average price is $731.33. The firm has a market cap of $64.71 billion, a price-to-earnings ratio of 15.46, a P/E/G ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm posted $11.86 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.